Cat No.
CEI-0151
Description
SB 202190 (FHPI) can potently inhibit p38alpha and p38beta with IC50 of 50 nM and 100 nM.
CAS No.
152121-30-7
Targets
p38alpha, p38beta
Chemical Name
4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol
M.Wt
331.34
Purity
>99%
Solubility
DSMO 66 mg/mL Water
Storage
2 years at -20 centigrade
In vitro
SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190.
In vivo
In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control.
